Symbols

SNDX

Syndax·NASDAQ

--(--)

SNDX fundamentals

SNDX Q4 2025 Earnings

Syndax (SNDX) released its earnings on Feb 26, 2026: revenue was 68.73M (YoY +794.90%), beat estimates; EPS was -0.78 (YoY +29.09%), missed estimates.

Revenue / YoY

68.73M

+794.90%

EPS / YoY

-0.78

+29.09%

Report date

Feb 26, 2026

SNDX Earnings Call Summary for Q4,2025

Revenue Surpassing Expectations: 2025 total revenue of $172.4 million, with Revuforj and Niktimvo driving 72% and 24% of sales, respectively.
Market Leadership: 38% QoQ growth in Revuforj and 22% in Niktimvo, with Revuforj capturing >30% of NPM1 new patient starts in Q4.
Pipeline Catalysts: Phase II IPF data expected Q4 2026 and frontline Revuforj trials poised to unlock $5+ billion market opportunity.
Financial Strength: $394 million cash balance supports 2026 expenses without dilution, with Niktimvo margin contribution set to expand.

Earnings

EPS

Revenue

Revenue & Expenses

SNDX has released its 2025 Q4 earnings report, with revenue of 68.73M, reflecting a YoY change of 794.90%, and net profit of -68.01M, showing a YoY change of 27.77%. The Sankey diagram below clearly presents SNDX's revenue sources and cost distribution.

Key Indicators

Syndax (SNDX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Syndax (SNDX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Syndax (SNDX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Syndax (SNDX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown